| Literature DB >> 32652045 |
Yuto Nakamura1, Shunbun Kita2, Yoshimitsu Tanaka1, Shiro Fukuda1, Yoshinari Obata1, Tomonori Okita1, Hiroyuki Nishida3, Yuki Takahashi4, Yusuke Kawachi1, Yuri Tsugawa-Shimizu1, Yuya Fujishima1, Hitoshi Nishizawa1, Yoshinobu Takakura4, Shigeru Miyagawa5, Yoshiki Sawa6, Norikazu Maeda7, Iichiro Shimomura1.
Abstract
Mesenchymal stem/stromal cells (MSCs) are cultured adult stem cells that originally reside in virtually all tissues, and the gain of MSCs by transplantation has become the leading form of cell therapy in various diseases. However, there is limited knowledge on the alteration of its efficacy by factors in recipients. Here, we report that the cardioprotective properties of intravenously injected MSCs in a mouse model of pressure-overload heart failure largely depend on circulating adiponectin, an adipocyte-secreted factor. The injected MSCs exert their function through exosomes, extracellular vesicles of endosome origin. Adiponectin stimulated exosome biogenesis and secretion through binding to T-cadherin, a unique glycosylphosphatidylinositol-anchored cadherin, on MSCs. A pharmacological or adenovirus-mediated genetic increase in plasma adiponectin enhanced the therapeutic efficacy of MSCs. Our findings provide novel insights into the importance of adiponectin in mesenchymal-progenitor-mediated organ protections.Entities:
Keywords: MSC; T-cadherin; TAC model; adiponectin; exosome; extracellular vesicle; heart failure; mesenchymal stem/stromal cell
Year: 2020 PMID: 32652045 DOI: 10.1016/j.ymthe.2020.06.026
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454